Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial ...

Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...

Acurx Pharmaceuticals’ DNA Polymerase IIIC inhibitors receives US patent: Staten Island, New York Wednesday, February 4, 2026, 15:00 Hrs [IST] Acurx Pharmaceuticals, Inc., a lat ...

A protein that prepares DNA for replication also prevents the replication process from running out of control, according to a new study by Weill Cornell Medicine researchers. The work, published Jan.

DNA pol IIIC inhibitors have been clinically validated with the first-generation inhibitor ibezapolstat (IBZ), now entering Phase 3 clinical trials for Clostridioides difficile infection. IBZ has ...

Andrés Aguilera's laboratory, in collaboration with that of Ralf Wellinger (both professors in the Department of Genetics at the University of Seville in CABIMER) and with PharmaMAR, has identified ...

STATEN ISLAND, N.Y., Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small ...